A new approach to cancer drug discovery

Scientists at The Scripps Research Institute (TSRI) have developed and demonstrated a promising new strategy for the discovery of novel anti-cancer therapies. The TSRI scientists, collaborating with scientists at Pfizer, used their new approach to find small-molecule inhibitors of a protein that is important for the growth of non-small-cell lung cancers (NSCLCs). These cancers represent about 85 percent of lung cancers and are relatively insensitive to drug treatment.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Related Links:

The number of elderly people with advanced lung cancer is increasing globally owing to the aging population and advances in cancer therapy [1]. More than 50% of patients diagnosed with lung cancer are aged>65 years, which is the lower limit for defining “elderly” in epidemiologic researches [2]. Non-small-cell lung cancer (NSCLC) accounts for 85% of all cases of lung cancer among both the elderly [3] and the adults. Although platinum-combination regimens including newer agents are the standard first-line chemotherapy for most patients with adva nced NSCLC, their use in elderly patients remains controversial [4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
ConclusionsThis case series represents the first description of potential skeletal adverse effects related to immune checkpoint inhibitors. These findings are important for providers caring for patients who experience musculoskeletal symptoms and may merit additional evaluation.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Publication date: Available online 3 October 2018Source: Chemico-Biological InteractionsAuthor(s): Pan Jiang, Hai Xu, Chuyue Xu, Aochang Chen, Lijun Chen, Ming Zhou, Ijaz ul Haq, Xiaoyue Wu, Zahula Mariyam, Qing FengAbstractLong non-coding RNAs (lncRNAs) have been identified to exert crucial roles in tumorigenesis and can serve as novel biomarkers for cancer therapy including lung cancer. Cisplatin is a first-line chemotherapeutic agent in non-small cell lung cancer (NSCLC), but the therapeutic effect is unsatisfactory, partly due to drug resistance. Emerging evidence showed that chemo-resistance is associated with acquisi...
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
Abstract Long non-coding RNAs (lncRNAs) have been identified to exert crucial roles in tumorigenesis and can serve as novel biomarkers for cancer therapy including lung cancer. Cisplatin is a first-line chemotherapeutic agent in non-small cell lung cancer (NSCLC), but the therapeutic effect is unsatisfactory, partly due to drug resistance. Emerging evidence showed that chemo-resistance is associated with acquisition of cancer stem cell (CSC)-like properties. Cisplatin resistance remains a major obstacle in the treatment of lung cancer, and its mechanism is still not fully elucidated. Meanwhile, CSCs have been invo...
Source: Chemico-Biological Interactions - Category: Molecular Biology Authors: Tags: Chem Biol Interact Source Type: research
Abstract Non-thermal plasma (NTP) treatment has been proposed as a potential approach for cancer therapy for killing cancer cells via generation of reactive oxygen species (ROS). As an antioxidant protein, Heme oxygenase-1 (HO-1) has been known to protect cells against oxidative stress. In this paper, we investigated the role of HO-1 activation in NTP-induced apoptosis in A549 cells. Distinctly increased ROS production and apoptosis were observed after NTP exposure. NTP exposure induced HO-1 expression in a dose- and time-dependent manner via activating the translocation of Nuclear factor (erythroid-derived 2)-l...
Source: Archives of Biochemistry and Biophysics - Category: Biochemistry Authors: Tags: Arch Biochem Biophys Source Type: research
Abstract Although epidermal growth factor receptor (EGFR) inhibitors have been used to treat non-small cell lung cancer (NSCLC) for decades with great success in patients with EGFR mutations, acquired-resistance inevitably occurs after long-term exposure to the treatment of EGFR inhibitors. Glycolysis is a predominant process for most cancer cells to utilize glucose, which referred to as the Warburg Effect. Targeting critical enzymes, such as pyruvate dehydrogenase kinase 1 (PDK1) that inversely regulating the process of glycolysis could be a promising approach to work alone or in combination with other treatments...
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharmacol Source Type: research
Abstract Non-small cell lung cancer (NSCLC) has a high mortality rate worldwide. Various treatments strategies have been used against NSCLC including individualized chemotherapies, but innate or acquired cancer cell drug resistance remains a major obstacle. Recent studies revealed that the Kelch-like ECH associated protein 1/Nuclear factor erythroid 2-related factor 2 (Keap1/Nrf2) pathway is intimately involved in cancer progression and chemoresistance. Thus, antagonizing Nrf2 would seem to be a viable strategy in cancer therapy. In the present study a traditional Chinese medicine, triptolide, was identified that ...
Source: Toxicology and Applied Pharmacology - Category: Toxicology Authors: Tags: Toxicol Appl Pharmacol Source Type: research
Authors: Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Gupta N, Johung KL, Klopp A, LaCasce AS, Lin C, Makarova-Rusher OV, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, Palella F, Ratner L, Rizza S, Rudek MA, Taylor J, Tomlinson B, Wang CJ, Dwyer MA, Freedman-Cass DA Abstract People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment disparities. Lack of guidelines and provider education has le...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Hongtao L, Xiaoqi G, Junni L, Feng X, Guodong B, Liang Y Abstract Chlorogenic acid (CGA), an ester with various pharmacological effects, is important in cancer therapy. However, the specific antitumor mechanism of CGA is not entirely clear, especially with respect to its suppression of non-small cell lung cancer (NSCLC). The present study was carried out to assess the effect of CGA on NSCLC, and the mechanism involved. Cell viability assay and colony formation assay revealed that CGA blocked the proliferative capacity of NSCLC cells in vitro. Results from the migration assay suggested that CGA also inhibit...
Source: Cellular and Molecular Biology - Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research
Conclusion: Our results suggest that miR-125b-1-3p exerts antitumor functions in NSCLC cells by targeting S1PR1. PMID: 30082521 [PubMed - in process]
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Non-Small Cell Lung Cancer | Pfizer | Pharmaceuticals